INT231412

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2008
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 8
Disease Relevance 3.13
Pain Relevance 0.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (NBN) nucleolus (NBN) chromosome (NBN)
nucleus (NBN) intracellular (NBN) cell cycle (NBN)
Anatomy Link Frequency
plasma 1
NBN (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 30 94.66 High High
tolerance 24 54.44 Quite High
beta blocker 6 14.20 Low Low
withdrawal 6 5.00 Very Low Very Low Very Low
abdominal pain 6 5.00 Very Low Very Low Very Low
Bioavailability 6 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
diclofenac 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 440 99.20 Very High Very High Very High
Hyperbilirubinemia 132 98.80 Very High Very High Very High
Lipodystrophy 30 98.22 Very High Very High Very High
Disorder Of Lipid Metabolism 102 92.64 High High
Viremia 12 87.92 High High
Sprains And Strains 6 87.44 High High
Infection 54 84.32 Quite High
Jaundice 40 79.12 Quite High
Syndrome 12 76.48 Quite High
Body Weight 12 67.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ATV bilirubin levels increased by 0.87 mg/dL, while it was 0.46 mg/dL using indinavir.
Positive_regulation (increased) of ATV
1) Confidence 0.55 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.75 Pain Relevance 0
However, in the AI424-007 trial, lipodystrophy continued to be infrequent and not significant compared to nelfinavir after 48 weeks on unboosted ATV.43
Positive_regulation (unboosted) of ATV associated with lipodystrophy
2) Confidence 0.40 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.41 Pain Relevance 0.03
It must be acknowledged that the approval of ATV was accelerated based on the results of another three clinical trials run in patients with virological failure under PI-containing regimens (Table 5).
Positive_regulation (accelerated) of ATV
3) Confidence 0.40 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.13 Pain Relevance 0
The metabolic indulgence of ATV was one of the most striking findings of the AI424-007 and AI424-008 studies.
Positive_regulation (indulgence) of ATV
4) Confidence 0.40 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.30 Pain Relevance 0
The compound inhibits the virus-specific processing of viral Gag and Gag-Pol poliproteins of HIV-1 group M subtype A, B, C, D, AE, AG, F, G, and J in infected cells, thus preventing formation of mature virions.1 As measure of potency, the concentration that inhibits 50% of viral replication (IC50) in the absence of human serum ranged from 0.58 ng/mL to 5.7 ng/mL in a panel of susceptible viruses isolated from 31 PI-naïve HIV-infected patients.2,3 The presence of 40% human serum in cell cultures increased ATV IC50 by 2.7- to 3.6-fold, as noticed for other PIs.
Positive_regulation (increased) of ATV associated with acquired immune deficiency syndrome or hiv infection and potency
5) Confidence 0.37 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.62 Pain Relevance 0.05
Consequently, ATV normal half-life (~7 h) is increased resulting in higher minimum concentration (Cmin), Cmax and AUC.1 Table 2 depicts the main pharmacokinetic parameters of ATV 400 and ATV/r 300/100 mg/day.1,14
Positive_regulation (increased) of ATV
6) Confidence 0.37 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.26 Pain Relevance 0
This dose increases the ATV minimum plasma concentrations (Cmin) and area under the plasma concentration-time curve (AUC) 5-fold and 3-fold higher, respectively, than can be attained with unboosted ATV 400 mg QD [8].
Positive_regulation (increases) of ATV in plasma
7) Confidence 0.34 Published 2008 Journal AIDS Res Ther Section Body Doc Link PMC2365957 Disease Relevance 0.05 Pain Relevance 0
As ritonavir 100 mg increases ATV Cmin by 3-fold higher than is attainable with unboosted ATV 400 mg QD, this dose compensates for the negative pharmacokinetic effects of TDF [7].
Positive_regulation (increases) of ATV
8) Confidence 0.34 Published 2008 Journal AIDS Res Ther Section Body Doc Link PMC2365957 Disease Relevance 0.54 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox